Stocks Health care NVCT
NASDAQ · Health careNuvectis Pharma, Inc. (NVCT)
It posted a net loss of $50.5M. At September 30, 2026 it held $140.7M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 4, 2026.
Key facts about Nuvectis Pharma, Inc.
- Net worth
- Nuvectis Pharma, Inc. has a market value (market cap) of $684.9M at the latest share price, and shareholders' equity of $126.6M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Cash flow
- In fiscal 2025 operations used $16M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 4, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Nuvectis Pharma, Inc.'s next report is expected around February 10, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Nuvectis Pharma, Inc. does
Nuvectis Pharma, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker NVCT.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$26.4M | -$1.32 | n/a |
| 2024 | n/a | -$19M | -$1.11 | n/a |
| 2023 | n/a | -$22.3M | -$1.43 | n/a |
| 2022 | n/a | -$19.1M | -$1.51 | n/a |
| 2022 | n/a | -$12.9M | -$3.02 | n/a |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Nuvectis Pharma, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 4, 2026
- November 4, 2026
- August 21, 2026
- August 21, 2026Other event 8-K
- August 6, 2026Passive stake (5% or more) SCHEDULE 13G
- August 4, 2026
- August 4, 2026
- June 30, 2026
- June 29, 2026Other event 8-K
- June 23, 2026
Insider trades
What the people running Nuvectis Pharma, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| August 3, 2026 | Carson Michael J.Vice President, Finance | Received as pay | 30,000 | - |
| June 30, 2026 | Bentsur RonChairman & CEO, Director, 10% owner | Bought | 12,500 | $250K |
| June 30, 2026 | Mosseri Marlio Charles10% owner | Boughtindirect | 50,000 | $916K |
| June 11, 2026 | Kaplan Matthew L.Director | Received as pay | 35,000 | - |
| June 11, 2026 | Sanchez JuanDirector | Received as pay | 35,000 | - |
| June 11, 2026 | Oliviero James F IIIDirector | Received as pay | 35,000 | - |
| June 11, 2026 | Hoberman KennethDirector | Received as pay | 35,000 | - |
| January 6, 2026 | Carson Michael J.Vice President, Finance | Received as pay | 61,200 | - |
Who owns NVCT
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Soleus Capital Management, L.P.13G, passive with 8 related filers | 5.1% | August 6, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 83 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Tang Capital Management LLC | 1,550,000 | new |
| BlackRock, Inc. | 1,001,285 | +236,844 |
| Perceptive Advisors LLC | 1,000,000 | new |
| Soleus Capital Management, L.P. | 1,000,000 | new |
| Vanguard Capital Management LLC | 872,482 | +212,603 |
| Iridian Asset Management LLC | 777,078 | +125,321 |
| Geode Capital Management, LLC | 432,273 | +48,168 |
| Occam Crest Management LP | 357,147 | -50,000 |
| Sphera Funds Management Ltd. | 382,945 | new |
| Baldwin Wealth Partners LLC | 382,015 | +3,390 |
| Alyeska Investment Group, L.P. | 275,000 | new |
| State Street Corp | 248,198 | +81,682 |
| Susquehanna International Group, Llp | 217,286 | +112,000 |
| Avidity Partners Management LP | 200,000 | new |
| Kalehua Capital Management LLC | 200,000 | new |
| Northern Trust Corp | 146,714 | +22,502 |
| Vanguard Fiduciary Trust Co | 127,554 | +12,712 |
| Vanguard Portfolio Management LLC | 118,297 | +26,143 |
| Citadel Advisors LLC | 115,532 | +37,107 |
| Oppenheimer & Co Inc | 73,566 | 0 |
Insiders
9 insiders reported holding 11,268,613 shares in total, about $236.9M at the last price.
| Holder | Shares |
|---|---|
| Bentsur RonChairman & CEO, Director, 10% owner | 3,688,424 |
| Mosseri Marlio Charles10% owner | 3,186,5763,186,576 held indirectly |
| Poradosu EnriqueChief Science & Business Off | 1,806,319 |
| Shemesh ShayChief Dev. & Ops. Officer | 1,793,068 |
| Carson Michael J.Vice President, Finance | 230,118 |
| Hoberman KennethDirector | 168,140 |
| Kaplan Matthew L.Director | 159,760 |
| Oliviero James F IIIDirector | 122,828 |
| Sanchez JuanDirector | 113,380 |
Questions about NVCT
What does Nuvectis Pharma, Inc. do?
Nuvectis Pharma, Inc. is a company in the Health care sector, listed on NASDAQ as NVCT. Its shares trade on NASDAQ under the ticker NVCT.
What is Nuvectis Pharma, Inc.'s net worth?
Nuvectis Pharma, Inc. has a market value (market cap) of $684.9M at the latest share price, and shareholders' equity of $126.6M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Nuvectis Pharma, Inc. profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $50.5M.
When did Nuvectis Pharma, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 4, 2026. It covers the period to September 30, 2026.
When is Nuvectis Pharma, Inc.'s next earnings report?
Nuvectis Pharma, Inc.'s next report is expected around February 10, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare NVCT with
Follow NVCT
Get an email when Nuvectis Pharma, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Nuvectis Pharma, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.